Vericel
- Market cap
- 2.09B
- P/E (TTM)i
- 84.88
- P/Bi
- 5.64
- EPSi
- 0.32
- Div yieldi
- 0.00%
- 52W posi
- 58%
Anonymous reader poll. Unscientific, not investment advice.
About Vericel
Vericel Corp. engages in the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of patients with diseases. Its product portfolio includes MACI and Epicel. The MACI portfolio is FDA-approved product that applies the process of tissue engineering to grow cells on scaffolds using healthy cartilage tissue from the patient's own knee. The Epicel portfolio provide skin replacement for patients who have deep dermal or full thickness burns. The company was founded on March 24, 1989 and is headquartered in Cambridge, MA.
- Founded
- 1989
- CEO
- Mr. Dominick C. Colangelo
- Employees
- 398
- Headquarters
- Cambridge, Massachusetts, United States of America
- Fiscal year end
- 12-31
- Website
- vcel.com
Company profile
- Exchange
- US
- Symbol
- VCEL
- Market-cap rank
- #2759
- Listing date
- 1970-01-01
- Market cap
- 2.09B
- Float cap
- 2.06B
- Shares out
- 51.21M
- Float shares
- 50.58M
Sectors & themes
Quote time 2026-10-08 04:26:33 · For reference only, not investment advice and not tailored to your situation.